Christoph U. Correll, MD

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

New data shared at ECNP Congress informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of Perseris to risperidone (Uzedy).

Check out these exciting updates from the recent RISE study on TV-46000, a subcutaneous long-acting injectable antipsychotic formulation of risperidone.

For the past 7 decades, there has only been 1 mechanism of action for schizophrenia treatment. Christoph Correll, MD, talks new options and cognitive impairment at the 2024 APA Annual Meeting.

Christoph Correll, MD, shares more on paliperidone palmitate 6-month for the treatment of schizophrenia.

Although psychotropic medications have revolutionized the treatment of many psychiatric disorders, the benefits sometimes come at a price.